drugset / Trial / NCT04710056
Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling
Summary
Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mibavademab | Monoclonal antibody | — | — |